Crescent Capital BDC (NASDAQ:CCAP) Issues Quarterly Earnings Results

Crescent Capital BDC (NASDAQ:CCAPGet Free Report) issued its earnings results on Monday. The company reported $0.36 earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.01), Zacks reports. The business had revenue of $5.12 million during the quarter, compared to analyst estimates of $37.12 million. Crescent Capital BDC had a negative net margin of 2.02% and a positive return on equity of 8.88%.

Crescent Capital BDC Stock Down 2.0%

CCAP traded down $0.23 on Wednesday, hitting $11.21. The company had a trading volume of 85,069 shares, compared to its average volume of 221,942. Crescent Capital BDC has a 52-week low of $10.64 and a 52-week high of $16.03. The stock has a fifty day simple moving average of $11.16 and a 200-day simple moving average of $12.38. The company has a debt-to-equity ratio of 1.35, a current ratio of 1.53 and a quick ratio of 1.53. The firm has a market capitalization of $413.04 million, a P/E ratio of -124.56 and a beta of 0.52.

Crescent Capital BDC Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Wednesday, September 30th will be issued a $0.34 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.36 annualized dividend and a yield of 12.1%. Crescent Capital BDC’s dividend payout ratio is -1,511.11%.

Insider Buying and Selling at Crescent Capital BDC

In related news, CEO Jason Breaux bought 5,000 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were acquired at an average cost of $11.19 per share, with a total value of $55,950.00. Following the completion of the acquisition, the chief executive officer owned 52,636 shares of the company’s stock, valued at $588,996.84. The trade was a 10.50% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Henry Chung purchased 4,500 shares of the company’s stock in a transaction dated Thursday, May 21st. The stock was purchased at an average price of $11.45 per share, for a total transaction of $51,525.00. Following the completion of the purchase, the president owned 20,722 shares in the company, valued at approximately $237,266.90. The trade was a 27.74% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 1.23% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Northwestern Mutual Wealth Management Co. purchased a new position in Crescent Capital BDC during the fourth quarter valued at approximately $27,000. VPR Management LLC raised its position in shares of Crescent Capital BDC by 150.0% during the 3rd quarter. VPR Management LLC now owns 5,000 shares of the company’s stock valued at $71,000 after purchasing an additional 3,000 shares during the period. Permanens Capital L.P. purchased a new position in shares of Crescent Capital BDC during the 3rd quarter valued at $147,000. XTX Topco Ltd purchased a new position in shares of Crescent Capital BDC during the 2nd quarter valued at $165,000. Finally, NewEdge Advisors LLC boosted its holdings in Crescent Capital BDC by 20.2% in the 4th quarter. NewEdge Advisors LLC now owns 12,279 shares of the company’s stock worth $173,000 after buying an additional 2,066 shares during the period. 49.46% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

CCAP has been the topic of a number of research analyst reports. Wall Street Zen lowered shares of Crescent Capital BDC from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. Oppenheimer lowered Crescent Capital BDC from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $19.00 to $16.00 in a research report on Friday, May 15th. Zacks Research upgraded shares of Crescent Capital BDC from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 21st. Wells Fargo & Company cut their price target on shares of Crescent Capital BDC from $12.00 to $11.00 and set an “equal weight” rating on the stock in a research report on Wednesday. Finally, B. Riley Financial reissued a “neutral” rating on shares of Crescent Capital BDC in a research note on Wednesday. Two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $13.70.

Check Out Our Latest Stock Analysis on CCAP

Crescent Capital BDC News Roundup

Here are the key news stories impacting Crescent Capital BDC this week:

  • Positive Sentiment: Crescent Capital BDC maintained its quarterly base dividend at $0.34 per share and declared a $0.03 special dividend. The regular payout implies an annualized yield of approximately 11.9%, which may support income-oriented investor interest. Crescent Capital BDC declares dividend and special dividend
  • Positive Sentiment: Management expects leverage to return to its target range during the second half of 2026 while continuing the $0.34 dividend. Lower leverage could improve balance-sheet flexibility and reduce financial risk if executed successfully. Crescent Capital BDC leverage outlook
  • Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day days-to-cover ratio. This suggests little measurable short-selling pressure, although the data may reflect a reporting anomaly.
  • Negative Sentiment: Second-quarter earnings were $0.36 per share, below the $0.37 consensus estimate and down from $0.46 a year earlier. Reported revenue of $5.12 million also fell far short of the $37.12 million consensus estimate, increasing concerns about operating performance. Crescent Capital BDC misses second-quarter estimates
  • Negative Sentiment: Wells Fargo lowered its price target from $12 to $11 and assigned an “equal weight” rating, signaling limited near-term upside based on its revised outlook. Wells Fargo price-target update

Crescent Capital BDC Company Profile

(Get Free Report)

Crescent Capital BDC, Inc is a closed-end, externally managed business development company that provides flexible financing solutions to middle market companies in the United States. Trading on the Nasdaq under the ticker CCAP, the firm offers investors exposure to a diversified portfolio of debt and equity instruments, targeting businesses with attractive risk-adjusted return profiles. Its primary objective is to generate current income through interest payments and potential capital appreciation via selective equity co-investments.

The company’s investment strategy emphasizes senior secured loans, unsecured second-lien loans, mezzanine debt, as well as preferred and common equity co-investments.

See Also

Earnings History for Crescent Capital BDC (NASDAQ:CCAP)

Receive News & Ratings for Crescent Capital BDC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crescent Capital BDC and related companies with MarketBeat.com's FREE daily email newsletter.